RxDoctor Payments Data

Mary Thompson, APRN

Family · Vernon, TXNPI 1649885021

Payments from drug & device makers

$949in general payments, 2019–2025

Across 45 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$265
  • AstraZeneca$161
  • AbbVie$125
  • Abiomed$117
  • Takeda Pharmaceuticals U.S.A., Inc.$113
  • Bayer$59
  • plus $110 from 5 others

What the payments were for

  • Food & beverage$949100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$949 in reported general payments places this provider in the 65th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$92,358
Medicare patients
259
Services billed
2,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$106,870
MounjaroTirzepatide62$66,819
RybelsusSemaglutide44$51,724
EliquisApixaban61$41,092
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$33,116
TrulicityDulaglutide15$16,862
Tresiba Flextouch U-200Insulin Degludec17$12,114
JardianceEmpagliflozin17$10,277
EntrestoSacubitril/Valsartan12$8,645
JanuviaSitagliptin Phosphate12$6,618
LinzessLinaclotide12$6,384
Potassium Chloride197$4,061
Incruse ElliptaUmeclidinium Bromide11$3,576
Advair HfaFluticasone Propion/Salmeterol11$3,288
Levothyroxine Sodium451$2,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$265$158,594124 claims
Lilly USA, LLCMounjaro, Trulicity$41$83,68277 claims
AbbVieLinzess$125$6,38412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 15,456 family providers in Texas.

Other family in Vernon

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →